A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Multiple Myeloma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 700
- Started
- 31 May 2026
- Main results due
- 29 April 2029
- Study sites
- 173
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion criteria: * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory * Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication * Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment Exclusion criteria: * Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study * Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients * Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM * Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Study sites(173)
Alabama Oncology
Birmingham, Alabama, United States
Recruiting
Mayo Clinic 1
Phoenix, Arizona, United States
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Recruiting
Beverly Hills Cancer Center Clinical Research Advisors LLC
Beverly Hills, California, United States
Recruiting
UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
Recruiting
University of California Irvine Medical Center
Orange, California, United States
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, United States
Recruiting
University of Connecticut Health Center
Farmington, Connecticut, United States
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Recruiting
Memorial Cancer Institute
Pembroke Pines, Florida, United States
Recruiting
Emory University
Atlanta, Georgia, United States
Recruiting
Rush University System for Health
Chicago, Illinois, United States
Recruiting
Franciscan Health
Indianapolis, Indiana, United States
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Recruiting
Mission Cancer Blood University of Iowa Health Care
Waukee, Iowa, United States
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Recruiting
LSU Health Feist Weiller Cancer Center
Shreveport, Louisiana, United States
Recruiting
Johns Hopkins Hospital
Baltimore, Maryland, United States
Recruiting
Tufts Medical Center
Boston, Massachusetts, United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
University Of Minnesota Medical Center
Minneapolis, Minnesota, United States
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Recruiting
Astera Cancer Care
East Brunswick, New Jersey, United States
Recruiting
Christus St. Vincent Regional Cancer Center
Santa Fe, New Mexico, United States
Recruiting
New York Oncology Hematology
Albany, New York, United States
Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, United States
Recruiting
NYU Langone Health Manhattan
New York, New York, United States
Recruiting
New York Cancer and Blood Specialists
Shirley, New York, United States
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Recruiting
Gabrail Cancer Center
Canton, Ohio, United States
Recruiting
The Christ Hospital
Cincinnati, Ohio, United States
Recruiting
Dayton Physicians Network Urology
Dayton, Ohio, United States
Recruiting
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Recruiting
Bon Secours Saint Francis Cancer Center
Greenville, South Carolina, United States
Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Recruiting
Baylor University Medical Center
Dallas, Texas, United States
Recruiting
Joe Arrington Cancer Research Treatment Center
Lubbock, Texas, United States
Recruiting
Utah Cancer Specialists
Salt Lake City, Utah, United States
Recruiting
NorthWest Medical Specialties, PLLC
Tacoma, Washington, United States
Recruiting
St Vincent s Hospital Sydney
Darlinghurst, Australia
Recruiting
Canberra Hospital
Garran, Australia
Recruiting
Austin Hospital
Heidelberg, Australia
Recruiting
Macquarie University Hospital
Macquarie University, Australia
Recruiting
Box Hill Hospital
Melbourne, Australia
Recruiting
Royal Perth Hospital
Perth, Australia
Recruiting
Port Macquarie Base Hospital
Port Macquarie, Australia
Recruiting
Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia
Brasília, Brazil
Recruiting
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Recruiting
Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
Florianópolis, Brazil
Recruiting
Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
Joinville, Brazil
Recruiting
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Recruiting
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
Recruiting
Funfarme Sjrp
São José do Rio Preto, Brazil
Recruiting
Real e Benemerita Associacao Portuguesa de Beneficencia
São Paulo, Brazil
Recruiting
Clinica Medica Sao Germano LTDA
São Paulo, Brazil
Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil
Recruiting
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada
Recruiting
Showing 60 of 173 sites — filter to narrow it down. 173 of the 173 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07518186. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me